Monitoring the quality of SARS‐CoV‐2 virus detection in molecular diagnostic laboratories in the Eastern Mediterranean Region during the COVID‐19 pandemic
Influenza and Other Respiratory Viruses · 2023
DOI: 10.1111/irv.13217 ↗Kurz gefasst
Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2023. Verfasst von Luke W Meredith und 5 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Hazard Management, Department of Health Emergency World Health Organization, Eastern Mediterranean Regional Office Cairo Egypt. Hauptthemen laut MEDLINE: COVID-19, Influenza, Human. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization.
Abstract (Originalsprache)
Introduction
The COVID‐19 pandemic placed unprecedented stress on laboratories in the Eastern Mediterranean Region. Building on existing capacity for influenza diagnostics, countries introduced COVID‐19 diagnostic support to ~100% regional coverage. A key challenge during the expansion was maintaining quality testing in laboratories, ensuring that correct results were shared with medical facilities.
Methods
WHO organized two rounds of independently monitored severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) external quality assurance programs (EQAP). The Public Health Laboratory (PHL) division of WHO supplied external quality assurance (EQA) panels, from the Royal College of Pathologists of Australasia Quality Assurance Programme (RCPAQAP) Australia to laboratories not enrolled in recurring Global Influenza Surveillance and Response System (GISRS) quality assurance programs, in which national influenza centers routinely participate.
Results
Fifteen and 14 countries participated in PHL/EQAP for SARS‐CoV‐2 between 2020 and 2022. Concordance was consistent between rounds, reaching 96.4% and 89.9%. A separate assessment of GISRS/EQAP to national‐level laboratories identified high levels of response and concordance for SARS‐CoV‐2 (100% response, 93% concordance), which was reduced for influenza (50% response rate, 80% concordance), reflecting the challenge of prioritizing pathogens during outbreaks.
Conclusion
The proliferation of laboratories in response to COVID‐19 was a success story from the pandemic. However, monitoring the quality of laboratories was challenging via existing EQAP. The addition of PHL/EQAP provided a mechanism to monitor performance of laboratories that were not designated as national influenza centers. While a high proportion of laboratories attained good results, continual emphasis on quality and enrollment in EQAP is key to ensuring sustainability of laboratory testing in future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Infectious Hazard Management, Department of Health Emergency World Health Organization, Eastern Mediterranean Regional Office Cairo Egypt.
ORCID-Profile: Luke W Meredith
Förderung
- World Health Organization
Zitieren
APA
Meredith, L. W., Aboualy, M., Ochola, R., Ozel, M., Abubakar, A., & Barakat, A. (2023). Monitoring the quality of SARS‐CoV‐2 virus detection in molecular diagnostic laboratories in the Eastern Mediterranean Region during the COVID‐19 pandemic. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.13217
Vancouver
Meredith LW, Aboualy M, Ochola R, Ozel M, Abubakar A, Barakat A. Monitoring the quality of SARS‐CoV‐2 virus detection in molecular diagnostic laboratories in the Eastern Mediterranean Region during the COVID‐19 pandemic. Influenza and Other Respiratory Viruses. 2023. doi:10.1111/irv.13217
BibTeX
@article{Meredith2023,
author = {Meredith, Luke W and Aboualy, Mustafa and Ochola, Rachel and Ozel, Mehmet and Abubakar, Abdinasir and Barakat, Amal},
title = {Monitoring the quality of SARS‐CoV‐2 virus detection in molecular diagnostic laboratories in the Eastern Mediterranean Region during the COVID‐19 pandemic},
journal = {Influenza and Other Respiratory Viruses},
year = {2023},
doi = {10.1111/irv.13217}
}
EUVIMED